Home | Welcome to Contract Pharma   
Last Updated Thursday, June 20 2013
Print RSS Feed

Breaking News

Related Searches:
Eden Biodesign's Second MHRA Audit is Successful

May 13, 2009
Eden Biodesign has completed a successful second audit by the UK Medicines and Healthcare Products Regulatory Agency (MHRA), European Medicines Agency (EMEA) to manufacture Investigational Medicinal Products (IMPs) at its facility in Liverpool, UK.  Read More »
GSK Extends Aspen Strategic Pact

May 12, 2009
GlaxoSmithKline has agreed to extend its strategic relationship with South African-based Aspen Pharmacare Holdings Ltd., and to acquire a 16% share in the company.  Read More »
Sanofi-aventis Acquires Antisoma's Leukemia Drug

May 12, 2009
Sanofi-aventis U.S. has acquired commercial rights to Oforta (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug, from biotechnology company Antisoma.  Read More »
Sartorius Stedim Biotech Adds Single-Use Bioreactors

May 12, 2009
Sartorius Stedim Biotech expanded its technology portfolio with the addition of two prototypes of single-use bioreactors that operate based on novel mixing technologies.  Read More »
Roche, Tekmira Enter RNAi Development Pact

May 11, 2009
Tekmira Pharmaceuticals Corp. has entered into a product development agreement with Roche to advance Roche's first two RNA interference (RNAi) product candidates into human trials.  Read More »
ACORN CRO

May 11, 2009
Kristie H. Lively, RN, BSN has been appointed vice president, ACORN CRO. Ms. Lively will oversee all aspects of the company's operations and services.   Read More »
FDA Approves Lamictal ODT

May 11, 2009
Eurand received approval from the FDA for EUR-1048, to be marketed as GlaxoSmithKline's Lamictal ODT (lamotrigine) Orally Disintegrating Tablets.  Read More »
ChemWerth, Tianjin Tianyao Pharma Enter Steroid API Pact

May 8, 2009
ChemWerth entered a manufacturing partnership with Tianjin Tianyao Pharmaceuticals Co., Ltd., a China-based manufacturer and exporter of corticosteroid products.  Read More »
Gileads' Hypertension Drug Shows Promise

May 8, 2009
Gilead's DAR-311 (DORADO) Phase III trial evaluating its once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, achieved positive results.  Read More »
AAIPharma Acquires Xcelodose 600S system

May 8, 2009
AAIPharma has acquired the Xcelodose 600S capsule filling system, enhancing the company’s preclinical and early phase clinical GMP supply capabilities.   Read More »
Isotechnika, Paladin Enter R&D Pact

May 7, 2009
Isotechnika entered a strategic investment and collaboration with Paladin Labs under which Paladin will provide Isotechnika with $7.0 million of cash upfront and $4.4 million in R&D funding during the next 12 months.  Read More »
Financial Report: Enzon 1Q

May 7, 2009
Oncaspar sales were up 15% to $14.1 million. DepoCyt sales were $2.5 million (+25%).   Read More »
Merck Serono Begins Phase III Parkinson's Study

May 7, 2009
Merck Serono and partner Newron Pharmaceuticals SpA have initiated the SETTLE study to evaluate the efficacy and safety of a dose range of safinamide (50-100 mg once daily) as an add-on therapy to levodopa, in mid- to late-stage Parkinson's disease patien  Read More »
Financial Report: Charles River 1Q

May 6, 2009
Preclinical Services revenue was $140.0 million (-17%) due primarily to slower market demand.   Read More »
GSK To Sell U.S. Wellbutrin XL to Biovail

May 6, 2009
GlaxoSmithKline has entered into an agreement to divest full commercial rights to Wellbutrin XL in the U.S. to Biovail International Laboratories, for $510 million.  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: